. . . . . . . . . "Inecalcitol"@en . . . . . . . . . . "Investigated for use/treatment in prostate cancer, psoriasis and hyperparathyroidism."@en . . . . . "TX522"@en . . . . . . . . "# Wong MS, Delansorne R, Man RY, Vanhoutte PM: Vitamin D derivatives acutely reduces endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 2008 May 16;. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18487433 # Eelen G, Verlinden L, Van Camp M, Claessens F, De Clercq P, Vandewalle M, Bouillon R, Verstuyf A: Altered Vitamin D receptor-coactivator interactions reflect superagonism of Vitamin D analogs. J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):65-8. Epub 2005 Jul 20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16039117 # Company Website \"Link\":http://www.hybrigenics.com/Pharma/Pharma-Content/Inecalcitol-Development.html"@en . . . "Inecalcitol is an analogue of calcitriol, the naturally active metabolite of vitamin D. Calcitriol and their analogues activate the vitamin D receptor (VDR). Vitamin D has a major role in regulating calcium absorption from the gut, storage in mineral form in the bones, and excretion by the kidney and effectively prevents rickets in infants. Vitamin D and calcitriol can cause hypercalcemia at high or frequently repeated doses; in turn, hypercalcemia can cause kidney toxicity by accumulation of calcium-containing micro-crystals and heart and muscle dysfunction by impairing contractions. [Hybrigenics Website] The mechanism of action is currently unknown, but it is proposed that inecalcitol exerts its superagonistic action through enhancing coactivator binding by the VDR."@en . . . "experimental"@en . "19-nor-14-epi-23-yne-1,25 dihydroxyvitamin D3"@en . .